The purpose of open-label study is to evaluate the efficacy and safety of AO-128 (Voglibose)
0.6 mg/day in patients with impaired glucose tolerance (IGT) who had been non-responsive to
diet therapy and exercise therapy, and follow up the progress after the end of treatment in
patients who was assessed as normoglycemic.